Drug Repurposing, Rescue, and Repositioning, a new peer-reviewed journal, presents techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.
Repurposing allows human investigation early in the drug discovery process, speeding up the development of important therapeutics. Repurposing can be an important tool in dissecting complex disorders, discovering molecular targets, and unraveling disease processes leading to therapeutic compounds for drug discovery and development. Drug “rescue” refers to research using small molecules and biologics that previously were used in studies but not further developed and submitted for Food and Drug Administration (FDA) approval. Drug repositioning is a scientifically logical process for finding new uses for drugs in well-defined and selected patient populations. The process has attracted the attention of regulators; the NIH has launched its National Center for Advancing Translational Medicine (NCATS), with the goal of promoting drug repurposing by industry. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application.
Drug Repurposing, Rescue, and Repositioning coverage includes:
- Interpreting assay outputs to enable alternate drug target identification
- Pathway analysis and bioinformatics to identify and exploit drug promiscuity
- In silico technologies to identify alternate drug targets
- "Big Data" mining and side effect pattern analysis in clinical and healthcare repositories
- Knowledge extraction from literature and patents in support of target space extension
- Drug repurposing towards neglected and orphan diseases
- Drug reformulation and alternative routes of administration
- Cost containment and risk mitigation in drug or candidate re-development
- Obtaining and defending intellectual property for new uses of known compounds
- Designing and optimizing the approval process for new indications
- Drug Repurposing Patent News and Commentary update in each issue
Drug Repurposing, Rescue, and Repositioning is currently under the leadership of Aris Persidis, Biovista, Inc.; Hermann Mucke, Hermann Mucke Pharma Consultancy e.U; and other leading investigators. View the entire editorial board.
Audience includes: Drug discovery and developmental scientists, pharmaceutical and biotechnology researchers, disease foundation specialists, regulators, among others.
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.